公开(公告)号：US20230027495A1

公开(公告)日：2023-01-26

申请号：US17775279

申请日：2020-11-06

Applicant: Genmab A/S ,  MSD International GmbH

Inventor： Reshma Abdulla RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO ,  Anthony CAO ,  Shyra GARDAI

IPC: A61K47/68 ,  C07K16/28 ,  C07K16/36 ,  A61P35/00

Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

公开(公告)号：US20220088191A1

公开(公告)日：2022-03-24

申请号：US17053753

申请日：2019-05-07

Applicant: Genmab A/S ,  MSD International GmbH

Inventor： Reshma Abdulla RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO ,  Anthony CAO ,  Shyra GARDAI

IPC: A61K39/395 ,  A61K47/68 ,  A61P35/00

Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

公开(公告)号：US20210402003A1

公开(公告)日：2021-12-30

申请号：US17289616

申请日：2019-10-28

Applicant: Genmab A/S

Inventor： Reshma Abdulla RANGWALA ,  Sandra VERPLOEGEN ,  Esther C.W. BREIJ ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/22 ,  C07K16/36 ,  A61K9/00 ,  A61K45/06 ,  A61K39/395

Abstract: The invention provides an anti-VEGF antibody (e.g., bevacizumab) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such cervical cancer. The invention also provides compositions and kits comprising the anti-VEGF antibody (e.g., bevacizumab) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as cervical cancer.

公开(公告)号：US20210395384A1

公开(公告)日：2021-12-23

申请号：US17198199

申请日：2021-03-10

Applicant: Genmab A/S

Inventor： David SATJIN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: C07K16/30 ,  C07K16/36 ,  A61K47/68 ,  A61K45/06

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

公开(公告)号：US20210015939A1

公开(公告)日：2021-01-21

申请号：US16982008

申请日：2019-03-20

Applicant: Genmab A/S

Inventor： Reshma Abdulla RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO

IPC: A61K47/68 ,  A61P35/00 ,  A61K31/555 ,  A61K9/00

Abstract: The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.

公开(公告)号：US20180044431A1

公开(公告)日：2018-02-15

申请号：US15626866

申请日：2017-06-19

Applicant: GENMAB A/S

Inventor： Sandra VERPLOEGEN ,  David P.E. SATIJN ,  Rene M.A. HOET ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Vibeke Miller BREINHOLT ,  Eva EHRNROOTH ,  Ole BAADSGAARD ,  Tom VINK ,  Willam Karel BLEEKER ,  Mischa HOUTKAMP ,  Maroeska OUDSHOORN ,  Rob N. DE JONG

IPC: C07K16/36 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/36 ,  A61K39/395 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US20230416403A1

公开(公告)日：2023-12-28

申请号：US18062473

申请日：2022-12-06

Applicant: Genmab A/S

Inventor： Sandra VERPLOEGEN ,  David P. E. SATIJN ,  Rene M. A. HOET ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Vibeke Miller BREINHOLT ,  Eva EHRNROOTH ,  Ole BAADSGAARD ,  Tom VINK ,  Willem Karel BLEEKER ,  Mischa HOUTKAMP ,  Maroeska OUDSHOORN ,  Rob N. DE JONG

IPC: C07K16/36 ,  A61K39/395

CPC classification number: C07K16/36 ,  A61K39/395 ,  C07K2317/565 ,  A61K2039/505

Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US20220323582A1

公开(公告)日：2022-10-13

申请号：US17502774

申请日：2021-10-15

Applicant: GENMAB A/S

Inventor： Sandra VERPLOEGEN ,  Marije OVERDIJK ,  Riemke VAN DIJKHUIZEN ,  Willem Karel BLEEKER ,  Patrick VAN BERKEL ,  Paul PARREN ,  Steen LISBY

IPC: A61K39/395 ,  A61K51/10 ,  C07K16/28 ,  A61K47/68 ,  A61K31/7088 ,  A61K35/17 ,  A61K35/76 ,  A61K38/16 ,  A61K38/19 ,  A61K45/06 ,  C07K16/18

Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.

公开(公告)号：US20210107980A1

公开(公告)日：2021-04-15

申请号：US17053346

申请日：2019-05-07

Applicant: Genmab A/S

Inventor： Reshma Abdulla RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO ,  Anthony CAO ,  Shyra GARDAI

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/36 ,  A61K47/68 ,  A61K45/06

Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

公开(公告)号：US20190315880A1

公开(公告)日：2019-10-17

申请号：US16367933

申请日：2019-03-28

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: C07K16/30 ,  A61K47/68 ,  C07K16/36 ,  A61K45/06

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.